| Switch-group (n = 30) | Pirfenidone-naïve group (n = 64) | p value | |
---|---|---|---|---|
Just before initiation of pirfenidone | Just before initiation of nintedanib | |||
Characteristics | ||||
 Age | 71.0 [67.0, 75.0] | 72.0 [68.0, 74.8] | 72.0 [65.8, 75.3] | 0.903* |
 Gender (male/female) | 24 / 6 | 24 / 6 | 53 / 11 | 0.778* |
 Physique | ||||
  Height (cm) | 165 [158, 169] | 165 [158, 169] | 164 [160, 170] | 0.958* |
  Body weight (kg) | 61.4 [59.2, 66.0] | 54.9 [49.7, 64.4] | 63.2 [54.2, 73.1] | 0.01* |
  Body mass index | 22.6 [21.0, 24.9] | 21.0 [19.0, 23.6] | 23.9 [20.7, 26.2] | 0.001* |
  Body surface area (DuBois, m2) | 1.69 [1.62, 1.76] | 1.59 [1.48, 1.72] | 1.68 [1.54, 1.82] | 0.063* |
 Lung function test | ||||
  Forced vital capacity (L) | 2.36 [1.78, 3.52] | 1.68 [1.34, 1.99] | 2.21 [1.74, 2.66] | 0.001* |
  % Forced vital capacity (%) | 62.5 [51.0, 76.6] | 52.9 [43.7, 69.7] | 67.7 [55.9, 79.0] | 0.001* |
  % DLco (%) | 58.4 [46.7, 65.7] | 44.2 [40.9, 58.5] | 54.8 [47.6, 67.9] | 0.009* |
Nintedanib | ||||
 Administration period (month) | – | 5.30 [2.84, 11.8] | 6.13 [3.02, 14.5] | 0.415 |
 Discontinue within 6 months | – | 16 (53.3%) | 21 (32.8%) | 0.072 |
 Adverse events | ||||
  AST/ALT elevation | – | 19 (63.3%) | 46 (71.9%) | 0.475 |
  Diarrhea | – | 14 (46.7%) | 34 (53.1%) | 0.659 |
  Anorexia | – | 14 (46.7%) | 14 (21.9%) | 0.028 |
  Weight loss | – | 6 (20.0%) | 6 (9.3%) | 0.188 |
  Nausea | – | 2 (6.7%) | 11 (17.1%) | 0.213 |
  Fatigue | – | 3 (10.0%) | 5 (7.8%) | 0.707 |